Sistema de Salut de Catalunya
[Rodriguez-Iglesias M] Rhinology group of the Young-Otolaryngologists of the International Federations of Oto-rhinolaryngological Societies (YO-IFOS) Study Group, Dubai, United Arab Emirates. Servicio de Otorrinolaringología, Hospital Clínico Universitario de Santiago, Servicio Gallego de Salud, Santiago de Compostela, Spain. [Calvo-Henríquez C] Rhinology group of the Young-Otolaryngologists of the International Federations of Oto-rhinolaryngological Societies (YO-IFOS) Study Group, Dubai, United Arab Emirates. Servicio de Otorrinolaringología, Hospital Clínico Universitario de Santiago, Servicio Gallego de Salud, Santiago de Compostela, Spain. Investigación Traslacional de Enfermedades de la Vía Aérea (TRIAD), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain. [Martin-Jimenez D] Rhinology group of the Young-Otolaryngologists of the International Federations of Oto-rhinolaryngological Societies (YO-IFOS) Study Group, Dubai, United Arab Emirates. Unidad de Rinología y Cirugía de Base de Cráneo Anterior, Servicio de Otorrinolaringología, Hospital Universitario Virgen Macarena, Sevilla, Spain. [García-Lliberós A] Rhinology group of the Young-Otolaryngologists of the International Federations of Oto-rhinolaryngological Societies (YO-IFOS) Study Group, Dubai, United Arab Emirates. Servicio de Otorrinolaringología, Hospital General Universitari de València, València, Spain. [Maza-Solano J] Rhinology group of the Young-Otolaryngologists of the International Federations of Oto-rhinolaryngological Societies (YO-IFOS) Study Group, Dubai, United Arab Emirates. Unidad de Rinología y Cirugía de Base de Cráneo Anterior, Servicio de Otorrinolaringología, Hospital Universitario Virgen Macarena, Sevilla, Spain. Departamento de Cirugía, Universidad de Sevilla, Sevilla, Spain. [Moreno-Luna R] Unidad de Rinología y Cirugía de Base de Cráneo Anterior, Servicio de Otorrinolaringología, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Izquierdo-Domínguez A] Servei d’Al·lergologia, Hospital Universitari de Terrassa, Consorci Sanitari de Terrassa (CST), Terrassa, Spain. Unitat Al·lergologia-Otorrinolaringologia, Centro Médico Teknon, Barcelona, Spain. [Alobid I] Unitat de Rinologia i Base de Crani Anterior, Servei d’Otorrinolaringologia, Hospital Clínic, Barcelona, Spain. Institut d’Investigacions Biomèdiques Agustí Pi Sunyer (IDIBAPS), Barcelona, Spain. Centro de Investigación Biomèdica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Universitat de Barcelona, Barcelona, Spain
Departament de Salut
2025-09-03T11:15:30Z
2025-09-03T11:15:30Z
2025-02-05
Biologic therapy; Chronic rhinosinusitis with nasal polyps; Dupilumab; Monoclonal antibody; Quality of life
Dupilumab; Rinosinusitis crònica amb pòlips nasals; Teràpia biològica
Dupilumab; Rinosinusitis crónica con pólipos nasales; Terapia biológica
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials. Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.
Funding for open access publishing: Universidad de Sevilla/CBUA.
Article
Published version
English
Sinusitis; DISEASES::Respiratory Tract Diseases::Nose Diseases::Paranasal Sinus Diseases::Sinusitis; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal; PUBLICATION CHARACTERISTICS::Study Characteristics::Clinical Study::Clinical Trial::Controlled Clinical Trial::Randomized Controlled Trial::Pragmatic Clinical Trial; ENFERMEDADES::enfermedades respiratorias::enfermedades nasales::enfermedades de los senos paranasales::sinusitis; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales; CARACTERÍSTICAS DE PUBLICACIONES::características del estudio::estudio clínico::ensayo clínico::ensayo clínico controlado::ensayo clínico controlado aleatorizado::estudio clínico pragmático
Springer
Current Allergy and Asthma Reports;25(1)
https://www.doi.org/10.1007/s11882-025-01192-y
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by/4.0/
